RETRACTED ARTICLE: The value of FGF9 as a novel biomarker in the diagnosis of prostate cancer
This record is marked as retracted by the source. Review the publisher’s notice before using its findings.
Source abstract
Abstract
We, the Editors and Publisher of the journal Artificial Cells, Nanomedicine, and Biotechnology, have retracted the following article:Genggang Cui, Mingming Shao, Xingzhou Gu, Hongbo Guo, Shiqing Zhang, Jianlei Lu & Hongbin Ma (2019) The value of FGF9 as a novel biomarker in the diagnosis of prostate cancer. Artificial Cells, Nanomedicine, and Biotechnology, 47:1, 2241–2245, DOI: 10.1080/21691401.2019.1620250It has come to our attention that the full authorship list and affiliations for this manuscript, including the study site and ethics committee, were changed after the article was submitted. We have contacted the authors for an explanation, but we have not received a response within the requested timeframe. As determining authorship and the location of where the research was conducted is core to the integrity of published work, we are therefore retracting the article. The authors listed in this publication have been sent notification.We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as ‘Retracted’.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Fibroblast Growth Factor Research · Prostate Cancer Treatment and Research · Cardiovascular Disease and Adiposity
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Urology Surgery, The First People’s Hospital of Jining
Department of Urology Surgery, Yanzhou Branch of Jining Medical University
References
Reference metadata was not supplied for this record.